Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight

globenewswire.com
EDSA Listed as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. VERU Included as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. PLTR Listed as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. HLIO Listed as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. DRCT Mentioned as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. BHVN Listed as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. CART Listed as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. AMGN Mentioned as a key company in the COPD and Asthma markets, but no specific developments related to ARDS or other areas are detailed. AROW Listed as a key company in the COPD market, but no specific developments related to ARDS or other areas are detailed. AZN Mentioned as a key company in the COPD and Asthma markets, but no specific developments related to ARDS or other areas are detailed. GSK Mentioned as a key company in the COPD and Asthma markets, but no specific developments related to ARDS or other areas are detailed. NVS Listed as a key company in the COPD market, but no specific developments related to ARDS or other areas are detailed. SNDX Mentioned as a key company in the ARDS market with pipeline drugs, but no specific positive or negative developments are detailed. SNY Mentioned as a key company in the COPD and Asthma markets, but no specific developments related to ARDS or other areas are detailed. UNH Mentioned as a key company in the COPD market, but no specific developments related to ARDS or other areas are detailed. VRTX Listed as a key company in the COPD market, but no specific developments related to ARDS or other areas are detailed.

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight New York, USA, April 09, 2026 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight

The ARSD clinical trial analysis report delivers important insights into ongoing research of 45+ pipeline ARSD drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Acute Respiratory Distress Syndrome Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for acute respiratory distress syndrome across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the acute respiratory distress syndrome domain.

Acute Respiratory Distress Syndrome Clinical Trial Analysis Summary

Request a sample and discover the recent advances in ARSD drugs @ Acute Respiratory Distress Syndrome Pipeline Report

What is Acute Respiratory Distress Syndrome?

Acute Respiratory Distress Syndrome (ARDS) is a rapidly advancing condition seen in critically ill patients. Its primary complication involves the leakage of fluid into the lungs, severely impairing or preventing normal breathing and leading to dangerously low blood oxygen levels. ARDS typically develops in individuals who are already suffering from another serious illness or major trauma, resulting in fluid accumulation within the alveoli and disruption of pulmonary surfactant. The causes of ARDS are broadly classified into direct and indirect lung injuries. Direct causes include conditions such as pneumonia, aspiration, and physical trauma to the lungs. Indirect causes arise from systemic insults, including pancreatitis, severe infections (sepsis), blood transfusions, extensive burns, and adverse drug reactions.

Find out more about acute respiratory distress syndrome drugs @ Acute Respiratory Distress Syndrome Treatment

A snapshot of the Pipeline Acute Respiratory Distress Syndrome Drugs mentioned in the report:

Learn more about the emerging ARSD therapies @ Acute Respiratory Distress Syndrome Clinical Trials

Stuti Mahajan, consulting manager at DelveInsight, said that ARDS remains a high-burden critical care condition with significant unmet need, driven by its complex pathophysiology and lack of targeted pharmacological therapies. Despite advances in supportive care, mortality remains high, highlighting limited treatment impact. Emerging approaches such as anti-inflammatory and cell-based therapies show promise, but clinical heterogeneity continues to challenge development.

Recent Developments in Acute Respiratory Distress Syndrome Treatment Space

Scope of the Acute Respiratory Distress Syndrome Pipeline Report

Dive deep into rich insights for new acute respiratory distress syndrome treatments, visit @ Acute Respiratory Distress Syndrome Drugs

Table of Contents

For further information on the acute respiratory distress syndrome cure research, reach out @ Medication for Acute Respiratory Distress Syndrome Treatment

Related Reports

Acute Respiratory Distress Syndrome Epidemiology Forecast

Acute Respiratory Distress Syndrome Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted ARDS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Acute Respiratory Distress Syndrome Market

Acute Respiratory Distress Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ARDS companies, including MediciNova, Edesa Biotech, Light Chain Biosciences, Mesoblast Limited, Veru, APEPTICO Forschung und Entwicklung GmbH, Pluristem Therapeutics, Avalo Therapeutics, Boehringer Ingelheim, Genentech, Windtree Therapeutics, Biomarck Pharmaceuticals, Athersys, Healios, Direct Biologics, Biohaven Pharmaceutical, Arch Biopartners, ILTOO Pharma, Cartesian Therapeutics, AVEM HealthCare, Vitti Labs, LLC, GEn1E Lifesciences, MiNK Therapeutics, Longeveron Inc., Reven Pharmaceuticals, Inc., Dompé Farmaceutici S.p.A, Vasomune Therapeutics, Inc., Aerogen Pharma Limited, among others.

Chronic Obstructive Pulmonary Disease Market

Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic obstructive pulmonary disease companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Chronic Obstructive Pulmonary Disease Clinical Trial Analysis

Chronic Obstructive Pulmonary Disease Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key COPD companies, including Sanofi, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Verona Pharma plc, Immunotek, Yungjin Pharm. Co., Ltd., Pulmotect, Inc., Tetherex Pharmaceutical, CSL Behring, AstraZeneca, Novartis, Genentech, Vertex Pharmaceuticals, EmeraMed, Afimmune, Mereo BioPharma, Synairgen, Adamis Pharmaceuticals, Quercegen Pharmaceuticals LLC, Regend Therapeutics, Meridigen Biotech Co., Ltd., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell Regenerative Medicine, Arrowhead Pharmaceuticals, ProterixBio, RS BioTherapeutics, MitoRx, C4X Discovery, Respiratorius, ARK biosciences, Incannex, GNI Pharma, Celon pharma, Alveolus Bio, Kinaset therapeutics, Landos Biopharma, Parion Sciences, KeyMed Biosciences, Bioneer corporation, AlgiPharma, Palobiofarma, Dimerix Bioscience, Glenmark Pharmaceuticals, among others.

Asthma Market

Asthma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key asthma companies including GlaxoSmithKline, 4D Pharma plc, AstraZeneca, Suzhou Connect Biopharmaceuticals, Avillion, Pearl Therapeutics, ARS Pharmaceuticals, Sinomab, Avalo Therapeutics, Kymab, Sanofi, Cumberland Pharmaceuticals, Genentech, Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.